short-term co-administration of acid folicfor treating children and adolescents with autism

Double blind randomized controlled clinical trial of the effect of short-term co-administration of acid folic on children and adolescents with autism

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402043930N33

Enrollment

Registered

2014-08-16

Start date

2014-02-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pervasive developmental disorders. Childhood autism

Interventions

Intervention 1: Acid folic (5mg/day)+ risperidone (0.5 to 3 mg/day). Intervention 2: Placebo + risperidone (0.5 to 3 mg/day).

Treatment - Drugs

Placebo

Acid folic (5mg/day)+ risperidone (0.5 to 3 mg/day)

Placebo + risperidone (0.5 to 3 mg/day)

Eligibility

Sex/Gender

All

Age

3 Years to 19 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Autism according to DSM-IV diagnostic criteria; aged 3 to 19 years old. Exclusion Criteria: primary diagnosis of a psychotic disorder; active substance abuse or dependence; unstable medical condition.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Irritability. Timepoint: Every 4 weeks. Method of measurement: Abbrant Behavior Checklist.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: Week 2, 4, and 8. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Ansarifar

Shiraz University of Medical sciences

Ansarifar_p@yahoo.com+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026